Clinical Trials Logo

Clinical Trial Summary

A clinical case series will be conducted measuring upper lip hair suppression for cosmetic effects in a group of 25 adult women with hirsutism of the upper lip. The study will use a topical phytonutraceutical that contains two ingredients that have been shown to suppress hair growth. The serum contains Narcissus Tazetta Bulb Extract (0.2%) and a hemp-extract (0.15%) known to stimulate cannabinoid one (CB1) receptors. The subjects will use the serum nightly for 60 days. High-power ProScope photographs will be obtained at the philtrum (above the center of the upper lip) as a landmark. Prior to starting the serum subjects will grow their upper lip hair for seven days. Hair shafts will be counted and graded for thickness and color using a standard methodology. The subjects will then use the serum for 60 days and will not be allowed to use laser, waxing, bleaching or tweezing during the duration of the study. Only shaving will be allowed. At the end of the 60 day course the subjects will grow their lip hair for seven days and the high-power photographs will be repeated at the same location based on landmarks. An independent board-certified dermatologist will evaluate and grade the pre- and post- serum photographs for cosmetic effects, number and thickness of the hairs.


Clinical Trial Description

Hirsutism is defined as increased bodily and facial hair growth in females presenting in locations where hair is ordinarily minimal or absent. It affects almost 30% of adult females during their lifetime. Current treatments for hirsutism include the use of oral contraceptives or antiandrogens. These drugs and hormones are associated with adverse effects and they may not manifest results if at all for at least 6 months most cannot be used if the female is pregnant, breastfeeding, or trying to become pregnant. Many women find that a multipronged approach that includes direct hair removal (such as plucking, waxing, shaving, depilatories, bleaches and laser), suppression of androgen production with drugs. More recently an effective prescription topical cream, Eflornithine hydrochloride (brand name: Vaniqa) has become available to slow the growth of unwanted facial hair in women. It does not remove hair permanently. Noticeable results take approximately six to eight weeks, and once the cream is discontinued, hair returns to pretreatment levels after approximately eight weeks. Eflornithine cream may cause skin to redden. Narcissus Tarzetta Bulb Extract 0.02% IBR-Dormin applied topically reduced hair shaft elongation by 34%. The test also showed the hair follicle started the transition from growth to resting phase (telogen). A study of 3.0% topical extract revealed a delay of men's facial hair regrowth after shaving. Studies of endocannabinoids and phytocannabinoids that stimulate the cannabinoid one (CB1) receptor reveal that topical application inhibited hair shaft elongation and the proliferation of hair matrix keratinocytes, and induced intraepithelial apoptosis and premature hair follicle regression (catagen). A clinical case series from serial patients with hirsuitism (adult females) at a dermatology clinic will be conducted measuring upper lip hair suppression for cosmetic effects and change in hair shaft count and color. The study will use a topical phytonutraceutical containing Narcissus Tazetta Bulb Extract (0.2%) and a hemp-extract (0.15%) known to stimulate cannabinoid one (CB1) receptors. Based on prior studies the topical will work locally as a locally active topical without systemic absorption. The 25 subjects will use the serum nightly for 60 days. High-power ProScope photographs will be obtained at the philtrum (above the center of the upper lip) as a landmark. Prior to starting the serum subjects will grow their upper lip hair for seven days. Hair shafts will be counted and graded for thickness and color using a standard methodology. The subjects will then use the serum for 60 days and will not be allowed to use laser, waxing, depilatories, bleaching or tweezing during the duration of the study. Only shaving will be allowed. At the end of the 60-day trial the subjects will grow their lip hair for seven days and the high-power photographs will be repeated at the same location based on landmarks. An independent board-certified dermatologist will evaluate and grade the pre- and post-treatment photographs for cosmetic effects, number and thickness of the hairs. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT06003062
Study type Observational
Source Medical Life Care Planners, LLC
Contact Gregory L Smith, MD
Phone 4044514045
Email DrSmith@NeX-Therapeutics.com
Status Not yet recruiting
Phase
Start date September 1, 2023
Completion date December 1, 2023

See also
  Status Clinical Trial Phase
Completed NCT02103608 - Clinical Evaluation of Silk'n Glide for Face N/A
Not yet recruiting NCT00495443 - Enhanced Safety Aesthetic Laser System N/A
Active, not recruiting NCT00145288 - Prospective Study of Patients With Hirsutism Phase 2/Phase 3
Completed NCT00152048 - Evaluation of Eflornithine on Facial and Forearm Skin Phase 4
Enrolling by invitation NCT01461694 - Facial Hair Reduction Using Intense Pulsed Light (IPL) & Alexandrite Laser Phase 2/Phase 3
Not yet recruiting NCT00441948 - Enhanced Safety Laser Hair Removal System N/A
Completed NCT03673995 - Myoinositol Plus L-tyrosine, Selenium and Chromium in PCOS N/A
Recruiting NCT04979377 - Prevalence of Hyperandrogenism in Type 1 Diabetes
Completed NCT02494297 - DUS on the Prescribing Indications for CPA/EE in 5 European Countries
Completed NCT00960310 - Relative Bioavailability Study of Bicalutamide 50 mg Tablet and Casodex Following a 50 mg Dose in Healthy Subjects Under Fed Conditions Phase 1
Completed NCT02793557 - Investigation of FOL-005 on Clinical Safety and Effect on Hair Growth Phase 1/Phase 2
Completed NCT01817894 - Treatment With Topical Eflornithin After Laser Treatment in Women With Facial Hirsutism Phase 4
Completed NCT01555190 - Combination Therapy With Myo-inositol and Folic Acid Versus Myo-inositol Alone N/A
Completed NCT00143052 - Bone Status and Insulin Resistance in Hirsutism N/A
Recruiting NCT01338519 - Database Study on Patients With PCOS N/A
Recruiting NCT04292587 - Prevalence of Hirsutism in Turkey: Data of The Dermatoendocrinology Study Group
Completed NCT00959335 - Relative Bioavailability Study of Bicalutamide 50 mg Tablet and Casodex Following a 50 mg Dose in Healthy Subjects Under Fasting Conditions Phase 1
Not yet recruiting NCT00371930 - Photodynamic Therapy for Permanent Hair Removal Phase 1/Phase 2